Anti-SARS-CoV-1/2 S Protein Antibody, clone hu2B3E5 ZooMAb^® Chimeric Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.

Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.

Learn more about ZooMAb here.

Clone hu2B3E5 is a chimeric ZooMAb monoclonal antibody that specifically detects SARS-CoV-1/2 Spike protein. It targets an epitope within the extracellular domain.
ZHU1076 combines variable regions of mouse monoclonal antibody anti-SARS-CoV-1/2 Spike protein (ZMS1076) and constant region of human IgG1. We recommend an anti-human antibody as secondary antibody for detection (Example: AP309P Goat anti-human IgG antibody HRP).

Recombinant fragment corresponding to full-length extracellular domain from SARS-CoV virus spike protein.

Affinity Binding Assay: A representative lot of this antibody bound recombinant extracellular domain (ECD) of Spike protein with a KD of 4.2 x 10-6 and with the recombinant receptor binding domain (RBD) with a KD of 9.5 x 10-7.

Flow Cytometry Analysis: A representative lot detected SARS-CoV-1/2 S Protein in 293 cells transfected to express spike protein (Courtesy of Dr Thomas Moran, Center for Therapeutic Antibody Development).

ELISA Analysis: A representative lot detected SARS-CoV-1/2 S Protein in ELISA application. (Courtesy of Dr Thomas Moran, Center for Therapeutic Antibody Development).

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Anti-SARS-CoV-1/2 S Protein, clone hu2B3E5 ZooMAb, Cat. No. ZHU1076, is a chimeric recombinant Hu Monoclonal antibody (hu Fc region) that detects SARS-CoV-1/2 S Protein and is tested in Affinity Binding Assay, ELISA, Flow Cytometry and Western Blotting.

SARS-CoV-1/2 Spike glycoprotein (UniProt: P59594/P0DTC2; also known as S glycoprotein, E2, Peplomer protein) is encoded by the S gene (Gene ID: 1489668/43740568) in SARS-CoV-1/2 virus. The SARS-CoV-2 is a positive-strand RNA virus that causes severe respiratory syndrome in human. The mature SARS-CoV-2 contains 4 structural proteins: Envelope (E), Membrane (M), Nucleocapsid (N), and the Spike protein (S). E and M proteins help in viral assembly and N protein is needed for RNA synthesis. The S protein is a single-pass type I, homotrimeric, membrane glycoprotein that is responsible for virus binding and entry into host cell. It is synthesized with a signal peptide (aa 1-12), which is subsequently cleaved off to generate the mature protein that contains an extracellular domain (aa 13-1213), a transmembrane domain (aa 1214-1234), and a cytoplasmic domain 1235-1273). The S protein is further processed into S1 (aa 13-685) and S2 (aa 686-1273) subunits by host cell furin. The presence of a furin polybasic cleavage site in S protein from SARS-CoV-2 sets it apart from S protein in SARS-CoV that possesses a monobasic S1/S2 cleavage site. The S1 subunit has the receptor binding domain (RBD; aa 319-541) that mediates entry of SARS-CoV-2 into sensitive cells through the peptidase domain of host Angiotensin-converting enzyme 2 (ACE2) with high affinity (KD = 15 nM). The S2 protein, which is reported to be well conserved, is responsible for membrane fusion. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. This chimeric version was generated using FC region of human IgG.

Purified human monoclonal antibody IgG1 in buffer containing PBS with 5% Trehalose without preservatives

300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Data presented is the available current product information and provided as-is. These products have not been tested or verified in any additional applications, sample types, including any clinical use. Experimental conditions must be empirically derived by the user. Our Antibody Guarantee only covers tested applications stated herein and conditions presented in our product information and is not extended to publications.